Big Pharma’s Manufacturing Investment Plans
The pharma majors are targeting biologics and emerging markets in their manufacturing expansion activities and plans. Patricia Van Arnum reports ...Read more |
Initiating Early Access Programs in Europe
Executive Insight look at the specific considerations for launching an Early (or Expanded) Access Program in Europe ... Read more
|
Making Social Media Sell
Pharma companies have been widely embracing social media to advertise products, recruit staff, and report on CSP projects. But it is it doing any good, asks Patrick Homer ... Read more
|
US Biopharma Innovation in Trouble?
Next year it will cost $2.2 million in the US to submit an NDA or biologics license application (BLA) for FDA review, and $1 million for a supplement with clinical data. As a result, a slight drop in anticipated NDAs is expected. Will an ever-longer and more costly drug-development process that further squeeze pharma investment in R&D? ... Read more
|
Pharm Exec Global Digest Market Access Special
In the new issue: Develop a Market Access Roadmap; Embed Market Access in Your Organizational Culture; Initiating Early Access Programs in Europe; and More! ... Read more
|
| Products/Services Profiles |
|
| Sciformix |
 Product labeling– Increasing efficiency, enhancing quality, and delivering compliance
Pharmaceutical product labeling is a highly regulated and complex process. A product label is very specific in its content, with respect to safety data, adverse effects and compliance to country specific regulations.  Read more |
|
| Bio-Europe® 2013 |
 19th Annual International Partnering Conference
The 19th annual BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry.  Read more |
|
|
|
|
|
|
